Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer


Non-Small Cell Lung Cancer (NSCLC)

What is the purpose of this trial?

This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Vorinostat has been approved for use in patients with cutaneous T-cell lymphomas, but several pre-clinical studies suggest activity in lung cancer cell lines. Several HDAC inhibitors,including Vorinostat, may enhance the effect of radiotherapy, and this study will seek to confirm this.

Participation Guidelines

18 Years and older

Click here for detailed information about who can participate in this trial.

Merck Sharp & Dohme Corp.
Yale University
May 2009
Last Updated:
December 7, 2012
Study HIC#:

Clinicaltrials.gov ID: NCT00821951